US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sparton

18.51

+0.0000

Volume:- -

Turnover:- -

Market Cap:182.04M

PE:46.14

High:18.51

Open:18.51

Low:18.51

Close:18.51

Loading ...

Overview Company News Filings

BrainStorm Issues 2024 Letter to Shareholders

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Press Release: Outlook Therapeutics(R) Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Singaporean buyers in legal dispute with Malaysian developer over ownership of Johor condo purchases

Energy Transfer Signs Agreement to Supply Chevron 2.0 Million Tonnes of LNG Per Annum From Its Lake Charles LNG Export Facility

Opus Genetics receives FDA agreement under SPA for Phase 3 trial of APX3330

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Outlook Therapeutics® Streamlines Operations

Banca Monte dei Paschi di Siena SPA (0RK6) Receives a Rating Update from a Top Analyst

RBC Capital Keeps Their Hold Rating on Recordati Industria Chimica e Farmaceutica SPA (0KBS)

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Reply SPA (0RV0) Receives a Hold from Kepler Capital

Credito Emiliano SPA Credem (0K93) was downgraded to a Hold Rating at Jefferies

Meta Health signs non-binding term sheet to acquire 30% stake in Aios Bio Sciences

Eutelsat Group Exercises Its Put Option and Signs Share Purchase Agreement With EQT Infrastructure for the Sale of a Majority Stake in a New Entity That Will Hold Its Passive Ground Infrastructure Assets

V2Y Corporation enters into distribution agreement to sell vegetables and other products to countries in Southeast Asia

Genenta Science SPA (ADR) trading halted, volatility trading pause

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SPA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SPA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPA\",,,,,undefined,":{"symbol":"SPA","market":"US","secType":"STK","nameCN":"Sparton","latestPrice":18.51,"timestamp":1575925200000,"preClose":18.51,"halted":4,"volume":0,"delay":0,"floatShares":8332448,"shares":9834723,"eps":0.401149,"marketStatus":"Delisted","change":0,"latestTime":"04-03 06:16:07 EDT","open":18.51,"high":18.51,"low":18.51,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.401149,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743687000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":18.51,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SPA\",,,,,undefined,":{"symbol":"SPA","floatShares":8332448,"roa":"--","roe":"--","lyrEps":-0.839271,"shares":9834723,"dividePrice":0,"high":18.51,"amplitude":0,"preClose":18.51,"low":18.51,"week52Low":11.955,"pbRate":"2.41","week52High":22.89,"institutionHeld":0.623,"latestPrice":18.51,"eps":0.401149,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.401149,"open":18.51},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SPA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2495427065","title":"BrainStorm Issues 2024 Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2495427065","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495427065?lang=en_us&edition=fundamental","pubTime":"2024-12-30 21:00","pubTimestamp":1735563600,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 30, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders.2024 has been a very productive year for BrainStorm Cell Therapeutics, defined by remarkable milestones and achievements that have brought us closer to our mission of delivering groundbreaking therapies for neurodegenerative diseases. I am proud to share this summary of our accomplishments as we close the year with optimism and look forward to the promise of 2025.These results are particularly meaningful because they provide a quantifiable measure of NurOwn's biological impact, complementing clinical assessments of patient function and quality of life. Beyond NfL, exploratory analyses have highlighted potential correlations between NurOwn treatment and other biomarkers associated with inflammation and neuroprotection, further emphasizing the potential multifaceted benefits of our therapy. To","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/brainstorm-issues-2024-letter-shareholders-130000183.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainstorm-issues-2024-letter-shareholders-130000183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MSC","LU1363072403.SGD","BK4006","BK4575","LU0170899867.USD","LU0267386448.USD","BK4150","IE00BHPRN162.USD","SPA","LU0149725797.USD","CMC","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4139","LU0882574139.USD","LU0971096721.USD","IE00B1BXHZ80.USD","BCLI"],"gpt_icon":0},{"id":"2494800532","title":"Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2494800532","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494800532?lang=en_us&edition=fundamental","pubTime":"2024-12-27 21:05","pubTimestamp":1735304700,"startTime":"0","endTime":"0","summary":"LYTENAVA is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in H1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/27/3002234/0/en/Outlook-Therapeutics-Reports-Financial-Results-for-Fiscal-Year-2024-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1316542783.SGD","LU1852331112.SGD","LU0109392836.USD","LU1988902786.USD","LU1803068979.SGD","IE00BMPRXN33.USD","LU1880398554.USD","NICE","SPA","BK4566","BK4554","LENZ","LU2458330243.SGD","BK4529","LU0642271901.SGD","BK4573","LU1989764664.SGD","IE00BFMHRM44.USD","LU1303367103.USD","LU0127658192.USD","LU2264538146.SGD","LU2458330169.SGD","LU0056508442.USD","GFS","LU1242518857.USD","IE0009356076.USD","BK4512","BK4156","BK4141","IE00BMPRXR70.SGD","LU1951198990.SGD","UK","BK4023","BK4139","IE0004445239.USD","LU0823421416.USD","BK4205","BK4532","LU1923623000.USD","IE00B5949003.HKD","LU2098885051.SGD","BK4528","LU0390134368.USD","BK4534","LU1951200564.SGD","LU1242518931.SGD","LU0198837287.USD","LU0082616367.USD"],"gpt_icon":1},{"id":"2494080797","title":"Press Release: Outlook Therapeutics(R) Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2494080797","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494080797?lang=en_us&edition=fundamental","pubTime":"2024-12-27 21:05","pubTimestamp":1735304700,"startTime":"0","endTime":"0","summary":"-- LYTENAVA is the first and only approved ophthalmic formulation of. bevacizumab for the treatment of wet AMD in the European Union  and. United Kingdom ; First commercial launch anticipated in H1 CY25. -- Received NICE recommendation of LYTENAVA  for the. In May 2024, the European Commission granted Marketing Authorization for LYTENAVA  for the treatment of wet AMD in the EU. Additionally, in July 2024, the UK Medicines and Healthcare products Regulatory Agency  granted Marketing Authorization for LYTENAVA  for the same indication in the UK. In December 2024, the National Institute for Health and Care Excellence  recommended LYTENAVA  as an option for the treatment of wet AMD. Plans for a potential 2025 launch in the UK and Germany are ongoing. Outlook Therapeutics remains confident that ONS-5010/ LYTENAVA is an important therapy for the treatment of wet AMD in place of","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0082616367.USD","BK4528","LU2360106780.USD","LU2458330243.SGD","SPA","BK4512","BK4555","LU0823421333.USD","BK4205","IE0004445239.USD","LU0889565833.HKD","TM","LU2264538146.SGD","IE00BMPRXN33.USD","UK","LU1852331112.SGD","BK4233","LU1242518931.SGD","LENZ","LU1242518857.USD","03160","BK4534","LU0198837287.USD","LU1303367103.USD","BK4099","LU0823434583.USD","LU2054465674.USD","OTLK","NICE","LU1989764664.SGD","LU0642271901.SGD","IE00BFMHRM44.USD","BK4232","R","LU1951198990.SGD","IE00BMPRXR70.SGD","LU0823434740.USD","LU0823421416.USD","BK4532","LU0390134368.USD","LU1803068979.SGD","LU1880398554.USD","BK4573","GFS","IE0009356076.USD","LU1064131342.USD","IE00B5949003.HKD","BK4554"],"gpt_icon":1},{"id":"2494299618","title":"Singaporean buyers in legal dispute with Malaysian developer over ownership of Johor condo purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2494299618","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494299618?lang=en_us&edition=fundamental","pubTime":"2024-12-27 13:28","pubTimestamp":1735277312,"startTime":"0","endTime":"0","summary":"Some Johor condominiums are sold under a private lease scheme, where a buyer does not own the property but instead buys a lease. ","market":"us","thumbnail":"https://dam.mediacorp.sg/image/upload/s--ezVoGcND--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:cna,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2024/12/18/dsc_4610_copy.jpg?itok=w7o76LQ6","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--ezVoGcND--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:cna,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2024/12/18/dsc_4610_copy.jpg?itok=w7o76LQ6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/asia/singaporean-home-buyers-legal-dispute-malaysian-developer-ownership-johor-condo-private-lease-scheme-property-4827501","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["SPA","CFA.SI"],"gpt_icon":1},{"id":"2492482144","title":"Energy Transfer Signs Agreement to Supply Chevron 2.0 Million Tonnes of LNG Per Annum From Its Lake Charles LNG Export Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2492482144","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492482144?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:02","pubTimestamp":1734642120,"startTime":"0","endTime":"0","summary":"DALLAS, December 19, 2024----Energy Transfer LP  today announced its subsidiary, Energy Transfer LNG Export, LLC , has entered into a 20-year LNG Sale and Purchase Agreement  with Chevron U.S.A. Inc.  related to its Lake Charles LNG project. Under the SPA, Energy Transfer LNG will supply 2.0 million tonnes of LNG per annum  to Chevron. The LNG will be supplied on a free-on-board  basis and the purchase price will consist of a fixed liquefaction charge and a gas supply component indexed to the Henry Hub benchmark. The obligations of Energy Transfer LNG under the SPA are subject to Energy Transfer LNG taking a final investment decision  as well as the satisfaction of other conditions precedent.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KPVyStB1NsJRqOti22CgZw--~B/aD00NjI7dz0xNTgyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/1d03ef7f4b04ff3797f5a250aaf21fe9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KPVyStB1NsJRqOti22CgZw--~B/aD00NjI7dz0xNTgyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/1d03ef7f4b04ff3797f5a250aaf21fe9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/energy-transfer-signs-agreement-supply-210200321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B29SXL02.USD","LU0417517546.SGD","LU0320765646.SGD","LU0266512127.USD","LU0300736492.USD","LU1280957306.USD","BK4201","BK4570","ET","LU2133065610.SGD","FID","LU0314104364.USD","LU1929549753.HKD","BK4534","LU0868494708.USD","IE00BGHQF524.EUR","BK4590","LU0256863811.USD","BK4138","SUN","LU0320765489.SGD","BK4559","LU0868494617.USD","LU0251131958.USD","LU2237438978.USD","USAC","BK4592","LU0170899867.USD","LNG","SPA","BK4144","LU0048573561.USD","IE00B2Q91V27.USD","LU0278409577.USD","BK4561","LU0122376428.USD","LU1496350171.SGD","LU0640476718.USD","BK4588","CVX","LU0456854461.SGD","LU0234572021.USD","IE00B3CCJ963.GBP","LU0070302665.USD","LU2449327464.USD","BK4566","LU1066051498.USD","LU0098860793.USD","BK4550"],"gpt_icon":0},{"id":"2492120528","title":"Opus Genetics receives FDA agreement under SPA for Phase 3 trial of APX3330","url":"https://stock-news.laohu8.com/highlight/detail?id=2492120528","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492120528?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:05","pubTimestamp":1734613551,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) announced that it has reached agreement with the U.S. Food and Drug Administration, FDA, on a Special Protocol Assessment, SPA,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-receives-fda-agreement-under-spa-for-phase-3-trial-of-apx3330?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-receives-fda-agreement-under-spa-for-phase-3-trial-of-apx3330?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","SPA","BK4007"],"gpt_icon":0},{"id":"2492127426","title":"Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for    Phase 3 Trial of APX3330 in Diabetic Retinopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127426","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492127426?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":"AgreementReached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec.  19, 2024  (GLOBE NEWSWIRE) -- Opus Gen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/19/2999786/0/en/Opus-Genetics-Receives-FDA-Agreement-Under-Special-Protocol-Assessment-for-Phase-3-Trial-of-APX3330-in-Diabetic-Retinopathy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU1242518931.SGD","LU1951200564.SGD","BK4529","SPA","BK4573","IE00B5949003.HKD","LCA","LU2098885051.SGD","BK4588","LU2458330169.SGD","BK4534","LU0081259029.USD","LU1989764664.SGD","LU0082616367.USD","LU2458330243.SGD","BK4575","LU1880398471.USD","LU1316542783.SGD","LU2250418816.HKD","LU0719512351.SGD","LU2264538146.SGD","LU0889565833.HKD","LU1303367103.USD","LU1880398554.USD","IE00BMPRXN33.USD","LU0823434583.USD","IE00BMPRXR70.SGD","LU0823434740.USD","IE0009356076.USD","BK4585","LU1951198990.SGD","LU1988902786.USD","IE0004445239.USD","BK4141","LU1852331112.SGD","LU0109392836.USD","LU0823421333.USD","LU0127658192.USD","BK4554","LU0642271901.SGD","BK4512","BK4532","LU0979878070.USD","LU1242518857.USD","LU0823421416.USD","LU1923623000.USD","AMD","LU0198837287.USD","LU1803068979.SGD"],"gpt_icon":1},{"id":"2491858503","title":"Outlook Therapeutics® Streamlines Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2491858503","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491858503?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:30","pubTimestamp":1734125400,"startTime":"0","endTime":"0","summary":"Full NORSE EIGHT Data Readout Expected January 2025ISELIN, N.J., Dec.  13, 2024  (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory app","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/13/2997055/0/en/Outlook-Therapeutics-Streamlines-Operations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NICE","BK4532","BK4512","LU0823434740.USD","BK4573","LU0642271901.SGD","LU1951198990.SGD","LU0390134368.USD","LU1852331112.SGD","LU1880398471.USD","LU2458330243.SGD","UK","IE00BMPRXN33.USD","LENZ","GFS","BK4585","LU0198837287.USD","LU2458330169.SGD","LU0823434583.USD","LU1988902786.USD","LU0081259029.USD","BK4141","BK4588","LU0889565833.HKD","LU0823421333.USD","BK4566","LU1303367103.USD","LU1242518857.USD","BK4528","BK4233","BK4554","LU0823421416.USD","LU1242518931.SGD","LU2264538146.SGD","IE0004445239.USD","IE00BMPRXR70.SGD","LU0082616367.USD","BK4205","BK4529","LU0127658192.USD","BK4156","LU2250418816.HKD","IE00B5949003.HKD","SPA","LU2360106780.USD","BK4023","IE00BFMHRM44.USD","BK4534"],"gpt_icon":1},{"id":"2491052348","title":"Banca Monte dei Paschi di Siena SPA (0RK6) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2491052348","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491052348?lang=en_us&edition=fundamental","pubTime":"2024-12-13 16:16","pubTimestamp":1734077810,"startTime":"0","endTime":"0","summary":"In a report released today, Paola Sabbione from Barclays maintained a Buy rating on Banca Monte dei Paschi di Siena SPA (0RK6 – Research Report). T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/banca-monte-dei-paschi-di-siena-spa-0rk6-receives-a-rating-update-from-a-top-analyst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/banca-monte-dei-paschi-di-siena-spa-0rk6-receives-a-rating-update-from-a-top-analyst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPA"],"gpt_icon":0},{"id":"2491973393","title":"RBC Capital Keeps Their Hold Rating on Recordati Industria Chimica e Farmaceutica SPA (0KBS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491973393","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491973393?lang=en_us&edition=fundamental","pubTime":"2024-12-13 09:51","pubTimestamp":1734054673,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Alistair Campbell maintained a Hold rating on Recordati Industria Chimica e Farmaceutica SPA (0KBS – Research Report) on Decemb...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-hold-rating-on-recordati-industria-chimica-e-farmaceutica-spa-0kbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-hold-rating-on-recordati-industria-chimica-e-farmaceutica-spa-0kbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPA"],"gpt_icon":0},{"id":"2490530148","title":"Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival","url":"https://stock-news.laohu8.com/highlight/detail?id=2490530148","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490530148?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:00","pubTimestamp":1733918400,"startTime":"0","endTime":"0","summary":"Positive topline data for CAN-2409 viral immunotherapy achieved primary endpoint by demonstrating statistically significant and clinically meaningful benefit when combined with radiation therapy for intermediate-to-high risk, localized prostate cancer. The safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identified. The phase 3 clinical trial was conducted under a Special Protocol Assessment  with the FDA. CAN-2409 is an investigational, off-the-shelf, replication-defective adenovirus that delivers the herpes simplex virus thymidine kinase  gene to tumor cells. CAN-2409, when administered with valacyclovir, is designed to induce immunogenic cell death of tumor cells with exposure of tumor antigens in the context of an activated tumor microenvironment. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the tumor, based on in situ vaccination against a variety of tumor anti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OVaui3MA0nAIzdRidF5_Jg--~B/aD0xNTE4O3c9MzMyNTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0967bb083514f87a91b7c0ba0cacf3b2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OVaui3MA0nAIzdRidF5_Jg--~B/aD0xNTE4O3c9MzMyNTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0967bb083514f87a91b7c0ba0cacf3b2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/candel-therapeutics-announces-2409-achieved-120000345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","CADL","BK4084","BK4107","BK4585","BK4600","BK4192","LU1668664300.SGD","SPA","DFS","BK4170","BK4595","BK4165","BK4588","BK4166","BK4533","LU1861220207.SGD","BK4139","LU1791807156.HKD","LENZ","BK4526","LU0106831901.USD","PSA","LU0053666078.USD","LU1861217088.USD","ADT","BK4217","L","LU2360107671.USD"],"gpt_icon":1},{"id":"2489447471","title":"Reply SPA (0RV0) Receives a Hold from Kepler Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2489447471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489447471?lang=en_us&edition=fundamental","pubTime":"2024-12-06 09:36","pubTimestamp":1733448970,"startTime":"0","endTime":"0","summary":"Kepler Capital analyst Hugo Paternoster maintained a Hold rating on Reply SPA (0RV0 – Research Report) on December 4 and set a price target of €145...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/reply-spa-0rv0-receives-a-hold-from-kepler-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/reply-spa-0rv0-receives-a-hold-from-kepler-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4134","RPYTF","SPA"],"gpt_icon":0},{"id":"2489463595","title":"Credito Emiliano SPA Credem (0K93) was downgraded to a Hold Rating at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2489463595","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489463595?lang=en_us&edition=fundamental","pubTime":"2024-12-05 23:16","pubTimestamp":1733411793,"startTime":"0","endTime":"0","summary":"In a report released on December 3, Marco Nicolai CFA from Jefferies downgraded Credito Emiliano SPA Credem (0K93 – Research Report) to a Hold, wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/credito-emiliano-spa-credem-0k93-was-downgraded-to-a-hold-rating-at-jefferies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/credito-emiliano-spa-credem-0k93-was-downgraded-to-a-hold-rating-at-jefferies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPA"],"gpt_icon":0},{"id":"2489123066","title":"Meta Health signs non-binding term sheet to acquire 30% stake in Aios Bio Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2489123066","media":"Ashley Lo","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489123066?lang=en_us&edition=fundamental","pubTime":"2024-12-04 10:04","pubTimestamp":1733277841,"startTime":"0","endTime":"0","summary":"A purchase price is currently under further negotiations between the parties. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/deals-joint-ventures-alliances/meta-health-signs-non-binding-term-sheet-acquire-30-stake-aios?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["SPA","BK6073","BK6514","5DX.SI"],"gpt_icon":0},{"id":"2488968285","title":"Eutelsat Group Exercises Its Put Option and Signs Share Purchase Agreement With EQT Infrastructure for the Sale of a Majority Stake in a New Entity That Will Hold Its Passive Ground Infrastructure Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2488968285","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488968285?lang=en_us&edition=fundamental","pubTime":"2024-12-02 15:00","pubTimestamp":1733122800,"startTime":"0","endTime":"0","summary":"Eutelsat Group  has exercised the put option signed with EQT Infrastructure VI fund  on 9th August 2024 regarding a majority stake in a newly created entity that will hold Eutelsat’s passive ground infrastructure assets. This decision follows the completion of the consultation processes with relevant employee representative bodies of Eutelsat.The exercise of the put option led to the signing of a binding Share Purchase Agreement  between Eutelsat and EQT.The transaction values the new entity at an enterprise value of 790m. It remains subject to customary conditions precedent, and closing of the deal is expected in the first quarter of calendar year 2026.Such forward-looking statements involve known and unknown risks. For illustrative purposes only, such risks include but are not limited to: risks related to the health crisis; operational risks related to satellit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eutelsat-group-exercises-put-option-070000481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3B42.SGD","ETCMY","LU0006061336.USD","BK4084","SPA","LEO","BK4585","EUTLF","BK4213","BK4100","GEO","EQT","IE0002270589.USD","BK4547","IE00B19Z3581.USD","BK4516","IE00B7SZLL34.SGD","BK4165","BK4588"],"gpt_icon":0},{"id":"2488691981","title":"V2Y Corporation enters into distribution agreement to sell vegetables and other products to countries in Southeast Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2488691981","media":"Felicia Tan","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488691981?lang=en_us&edition=fundamental","pubTime":"2024-12-01 09:11","pubTimestamp":1733015516,"startTime":"0","endTime":"0","summary":"V2Y Corp, which was previously known as Synagie Corporation, obtained the mandate to diversify its business from its shareholders on Oct 8.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/deals-joint-ventures-alliances/v2y-corporation-enters-distribution-agreement-sell-vegetables?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["BK6124","SPA","BK6521","BK4212","JVA"],"gpt_icon":0},{"id":"2487550666","title":"Genenta Science SPA (ADR) trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2487550666","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487550666?lang=en_us&edition=fundamental","pubTime":"2024-11-29 22:35","pubTimestamp":1732890920,"startTime":"0","endTime":"0","summary":"09:30 EST Genenta Science (GNTA) SPA (ADR) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genenta-science-spa-adr-trading-halted-volatility-trading-pause-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genenta-science-spa-adr-trading-halted-volatility-trading-pause-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPA","GNTA","BK4139"],"gpt_icon":0},{"id":"2486206948","title":"Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2486206948","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486206948?lang=en_us&edition=fundamental","pubTime":"2024-11-27 22:27","pubTimestamp":1732717659,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc.  revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients.In the NORSE EIGHT trial, ONS-5010 did not meet the pre-specified noninferiority endpoint at week 8 set forth in the special protocol assessment  with the FDA.The pre-specified noninferiority endpoint was measured by mean change in best corrected visual acuity  from baseline to week 8.Also Read: Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Higher On Friday?However, the preliminary data from the trial demonstrated an improvement in vision and the presence of biologic activity, as well as a continued favorable safety profile for ONS-5010.ONS-5010/Lytenava  has already been granted Marketing Authorization in the European Union and the U.K.If approved by the FDA, Outlook Therapeutics plans to commercialize ONS-5010/Lytenava  directly in the U.S. It is also assessing partnering options for Lytenava  in Europe and other reg","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8v_R4crK7kDkzx_WuhTrLw--~B/aD01NzY7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/d2904339fe0ff76aa12d7f49659b541e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8v_R4crK7kDkzx_WuhTrLw--~B/aD01NzY7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/d2904339fe0ff76aa12d7f49659b541e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-eye-disease-focused-outlook-142739527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","LU0053671581.USD","BK4139","OTLK","ITT","LU0054578231.USD","SPA","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":3,"totalSize":168}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SPA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-02-06","symbol":"SPA","fiscalQuarterEnding":"2018/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1549429200000,"reportTimeType":"","actualEps":0.51},{"market":"US","date":"2018-11-08","symbol":"SPA","fiscalQuarterEnding":"2018/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"","actualEps":0.2},{"market":"US","date":"2018-09-13","symbol":"SPA","fiscalQuarterEnding":"2018/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1536811200000,"reportTimeType":"","actualEps":0.32},{"market":"US","date":"2018-05-09","symbol":"SPA","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1525838400000,"reportTimeType":"","actualEps":0.22},{"market":"US","date":"2018-02-06","symbol":"SPA","fiscalQuarterEnding":"2017/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1517893200000,"reportTimeType":"","actualEps":0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SPA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SPA\",market:\"US\",delay:false,,,undefined,":{}}}